YUHIBDO
DEAD

Serial Number

90822277

Owner

Bristol-Myers Squibb Company

Attorney

Marilyn F. Kelly

Filing Date

Jul 12, 2021

Add to watchlist:

No watchlists yet
View on USPTO

YUHIBDO Trademark

Serial Number: 90822277

YUHIBDO is a trademark filed by Bristol-Myers Squibb Company on July 12, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

July 12, 2021

Registration Date

Not Registered

Published for Opposition

November 22, 2022

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 23, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 23, 2026 ABN6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 23, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 23, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2025 EXRA
SOU EXTENSION 5 GRANTED
Dec 10, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 10, 2025 AITU
SOU EXTENSION 5 FILED
Jun 24, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Jun 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jan 7, 2025 EX4G
SOU EXTENSION 4 FILED
Jan 7, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 7, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 8, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jul 8, 2024 EX3G
SOU EXTENSION 3 FILED
Jul 8, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 8, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 4, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jan 2, 2024 EX2G
SOU EXTENSION 2 FILED
Jan 2, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 2, 2024 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 12, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jul 10, 2023 EX1G
SOU EXTENSION 1 FILED
Jul 10, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 10, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 17, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 22, 2022 NPUB
PUBLISHED FOR OPPOSITION
Nov 22, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 2, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 13, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 13, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 13, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 13, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 13, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 14, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 13, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 13, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 16, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 16, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 16, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 9, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 16, 2021 NWOS
NEW APPLICATION ENTERED
Jul 15, 2021 NWAP